These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Nabhan C N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391 [No Abstract] [Full Text] [Related]
44. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer. Wesley JD; Whitmore J; Trager J; Sheikh N Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520 [TBL] [Abstract][Full Text] [Related]
45. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Antonarakis ES; Drake CG Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456 [TBL] [Abstract][Full Text] [Related]
46. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Tanimoto T; Hori A; Kami M N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392 [No Abstract] [Full Text] [Related]
47. Current role of immunotherapy for the treatment of prostate cancer. Porfyris O; Kalomoiris P J BUON; 2013; 18(4):809-17. PubMed ID: 24344002 [TBL] [Abstract][Full Text] [Related]
48. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
49. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related]
50. Prostate cancer immunology - an update for Urologists. Rajarubendra N; Lawrentschuk N; Bolton DM; Klotz L; Davis ID BJU Int; 2011 Apr; 107(7):1046-51. PubMed ID: 21070575 [TBL] [Abstract][Full Text] [Related]
51. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Dawson NA; Roesch EE Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782 [TBL] [Abstract][Full Text] [Related]
52. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. Sutherland SIM; Ju X; Horvath LG; Clark GJ Front Immunol; 2021; 12():641307. PubMed ID: 33854509 [TBL] [Abstract][Full Text] [Related]
53. [Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer]. Kubáčková K Klin Onkol; 2015; 28 Suppl 4():4S69-72. PubMed ID: 26647892 [TBL] [Abstract][Full Text] [Related]
54. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. Madan RA; Schwaab T; Gulley JL J Natl Compr Canc Netw; 2012 Dec; 10(12):1505-12. PubMed ID: 23221788 [TBL] [Abstract][Full Text] [Related]
55. Development of novel immune interventions for prostate cancer. Agarwal N; Padmanabh S; Vogelzang NJ Clin Genitourin Cancer; 2012 Jun; 10(2):84-92. PubMed ID: 22409862 [TBL] [Abstract][Full Text] [Related]
56. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Cheever MA; Higano CS Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425 [TBL] [Abstract][Full Text] [Related]